TransMedics Group, Inc. - Common Stock (TMDX)

Discover how TransMedics Group (TMDX) exemplifies a powerful growth investing strategy with explosive sales, earnings growth, and soaring profitability.

TransMedics shares fell 9% in after-hours trading after its third-quarter results showed strong year-over-year growth but a sequential slowdown and margin pressure.

TransMedics (TMDX) Q3 2025 Earnings Transcript

TransMedics (TMDX) Q3 2025 results show a mixed picture: EPS of $0.66 beat estimates by 84.6%, but revenue of $143.82M slightly missed forecasts.

It might be worth buying these companies before the market notices they are undervalued.

TransMedics (TMDX) is a top GARP stock with explosive revenue & earnings growth, strong profitability, and a reasonable valuation relative to its industry peers.

These stocks are crushing the market this year, and there is likely plenty of upside ahead.

TransMedics Group (NASDAQ: TMDX) has outperformed the market over the past 5 years by 37.76% on an annualized basis producing an average annual return of 52.39%. Currently, TransMedics Group has a market capitalization of $3.89 billion.

TransMedics (TMDX) is a top affordable growth stock with strong revenue & EPS growth, solid financial health, and a reasonable valuation in the organ transplant tech sector.

TransMedics (TMDX) shows explosive revenue & EPS growth, trading at a reasonable valuation given its strong position in the organ transplant tech market.

Affordable Growth investing balances strong revenue/earnings growth with fair pricing, as seen in TransMedics (TMDX), with high growth metrics, reasonable valuation, and stable finances.